Single center study shows changes in function in adults with SMA, highlighting care barriers.
To study longitudinal outcomes in adults with Type II and III SMA treated with nusinersen, risdiplam and switched (from nusinersen to risdiplam), comparing function and reasons for loss-to-follow-up.
No takes yet. Share an insight, caveat, or question.
Ananth et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: